What’s new

• SteriPort line set to commission by June 20.
• Solar project on the verge of going live.
• Debt trimmed from ₹234 cr to ₹204 cr post-balance sheet.

Why it matters

For a healthcare manufacturer, margin guidance of 24-25% is well above industry average. The upcoming capacity adds revenue visibility, and successful price pass-through shows pricing power. Debt reduction strengthens the balance sheet without sacrificing growth.

What we’re watching

• On-time commissioning of SteriPort and solar projects.
• Whether raw material costs stabilise or rise further.
• EBITDA margin trajectory once new capacity is fully utilised.

The full read

Amanta Healthcare's Q4 FY26 concall was heavy on operational milestones, not just numbers. The SteriPort line is slated to go live by June 20, followed closely by a solar project that should cut power costs. Management also flagged raw material price increases but confirmed a full pass-through to customers, preserving the margin profile. The balance sheet improved, with debt dropping from ₹234 crore to ₹204 crore. The headline guidance of 24-25% EBITDA margin on new capacity is what stands out — it sets a clear profitability benchmark against which all future quarters will be measured. For a company that just reported a routine earnings number, these are the operational catalysts that matter.

Primary source: BSE · NSE